Showing results (3021-3030 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigenG M Stuhlmiller, T L Darrow, D M Haupt, et al.
Cancer Immunology, Immunotherapy : CII|February 10, 2023
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibodyNoriyuki Nishiwaki, Kazuhiro Noma, Toshiaki Ohara, et al.
Cancer Immunology, Immunotherapy : CII|February 16, 2023
Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancerYao-Jun Yu, Na Shan, Li-Yi Li, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2022
Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunityJennie C Kim, Xian Liu, Karen Fitzgerald, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2023
Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCCTing Li, Jiang Guo, Yushen Liu, et al.
Cancer Immunology, Immunotherapy : CII|March 10, 2023
HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world studyMeiting Chen, Kai Yao, Manming Cao, et al.
Cancer Immunology, Immunotherapy : CII|February 16, 2026
Title: AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 studyKohei Hamada, Junzo Hamanishi, Akihiko Ueda, et al.
Cancer Immunology, Immunotherapy : CII|February 12, 2026
Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case seriesStéphanie Hermabessiere, Benjamin Jauzelon, Steven Marmain, et al.
Cancer Immunology, Immunotherapy : CII|March 4, 2025
Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy responseLi Liu, Peng Wu, Bingzhi Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 17, 2025
MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancerDeng Tang, Zhigang Mao, Sihan Chen, et al.
Pageof 652